Cited by 527Genetics and Neurodevelopmental DisordersNeuroscience and Neuropharmacology ResearchEpilepsy research and treatment

The DOI matches its Crossref record; 57 of the 60 references it cites were found in a registry or an index.

Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP

Yan, Q.J., Rammal, M., Tranfaglia, M., Bauchwitz, R.P.·2005·Neuropharmacology

DOI 10.1016/j.neuropharm.2005.06.004

Open this paper in CoChat — free account

Abstract

Fragile X Syndrome is the most common form of inherited mental retardation worldwide. A Fragile X mouse model, fmr1(tm1Cgr), with a disruption in the X-linked Fmr1 gene, has three substantial deficits observed in several strains: (1) sensitivity to audiogenic seizures (AGS), (2) tendency to spend significantly more time in the center of an open field, and (3) enlarged testes. Alterations in metabotropic glutamate receptor group I signaling were previously identified in the fmr1(tm1Cgr) mouse. In this study, we examined the effect of MPEP, an antagonist of the group I metabotropic glutamate receptor mGluR5, on audiogenic seizures and open field activity of fmr1(tm1Cgr) mice. Genetic analysis revealed synergistic reactions between fmr1(tm1Cgr) and inbred AGS alleles. In addition, AGS sensitivity due to the fmr1(tm1Cgr) allele was restricted during development. Examination of phenotypes combining mGluR5 inhibition and Fmr1 mutation indicated that absence of FMRP may affect mGluR5 signaling through indirect as well as direct pathways. All strains of fmr1(tm1Cgr) mice tested (FVB/NJ, C57BL/6J, and an F1 hybrid of the two) had a more excitable AGS pathway than wild-type, and consequently required more MPEP to achieve seizure suppression. At high doses of mGluR5 antagonists, a Fragile X specific tolerance (loss of drug activity) was observed. The tolerance effect could be overcome by a further increase in drug dose. In open field tests, MPEP reduced fmr1(tm1Cgr) center field behavio…

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.neuropharm.2005.06.004

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review.
Prut, L., & Belzung, C. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01272-x · Cited by 3,190
The open-field test: A critical review.
WALSH, R. N., & Cummins, R. A. (1976) · Psychological Bulletin · doi:10.1037/0033-2909.83.3.482 · Cited by 2,389
The mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580
Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: A novel test of anxiety in the rat
Pellow, S., & File, S. E. (1986) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(86)90552-6 · Cited by 1,534
Altered synaptic plasticity in a mouse model of fragile X mental retardation
Huber, K. M., Gallagher, S. M., Warren, S. T., & Bear, M. F. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122205699 · Cited by 1,349
Fmr1 knockout mice: A model to study fragile X mental retardation
THEDUTCHBELGIANFRAGILEXCONSOR (1994) · Cell · doi:10.1016/0092-8674(94)90569-x · Cited by 1,108
Abnormal dendritic spines in fragile X knockout mice: Maturation and pruning deficits
Comery, T. A., Harris, J. B., Willems, P. J., Oostra, B. A., Irwin, S. A., Weiler, I. J., & Greenough, W. T. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.10.5401 · Cited by 1,046
Deficient cerebellar long-term depression and impaired motor learning in mGluR1 mutant mice
Aiba, A., Kano, M., Chen, C., Stanton, M. E., Fox, G. D., Herrup, K., Zwingman, T. A., & Tonegawa, S. (1994) · Cell · doi:10.1016/0092-8674(94)90205-4 · Cited by 930
Metabotropic glutamate receptors: electrophysiological properties and role in plasticity
Anwyl, R. (1999) · Brain Research Reviews · doi:10.1016/s0165-0173(98)00050-2 · Cited by 799
Induction of LTP in the hippocampus needs synaptic activation of glutamate metabotropic receptors
Bashir, Z. I., Bortolotto, Z. A., Davies, C. H., Berretta, N., Irving, A. J., Seal, A., Henley, J. M., Jane, D. E., Watkins, J. C., & Collingridge, G. L. (1993) · Nature · doi:10.1038/363347a0 · Cited by 733

Show all 60 references

Sorted by citations

Items 101–200 of 527

Behavioral analysis of male and female Fmr1 knockout mice on C57BL/6 background
Ding, Q., Sethna, F., & Wang, H. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.05.046 · Cited by 131
AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome
Levenga, J., Hayashi, S., de Vrij, F. M. S., Koekkoek, S. K. E., van der Linde, H. C., Nieuwenhuizen, I. M., Song, C., Buijsen, R. A. M., Pop, A. S., Gomez‐Mancilla, B., et al. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.01.022 · Cited by 122
Of Men and Mice: Modeling the Fragile X Syndrome
Dahlhaus, R. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00041 · Cited by 133
Allosteric modulation of metabotropic glutamate receptors: Structural insights and therapeutic potential
Gregory, K. J., Dong, E. N., Meiler, J., & Conn, P. J. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.07.007 · Cited by 122
BC1 Regulation of Metabotropic Glutamate Receptor-Mediated Neuronal Excitability
Zhong, J. W., Chuang, S.-C., Bianchi, R., Zhao, W., Lee, H., Fenton, A. A., Wong, R. K. S., & Tiedge, H. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.3893-08.2009 · Cited by 120
Increased Expression of the PI3K Enhancer PIKE Mediates Deficits in Synaptic Plasticity and Behavior in Fragile X Syndrome
Gross, C., Chang, C.-W., Kelly, S. M., Bhattacharya, A., McBride, S. M. J., Danielson, S. W., Jiang, M. Q., Chan, C. B., Ye, K., Gibson, J. R., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.060 · Cited by 117
Exploring the Binding Mechanism of Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators in Clinical Trials by Molecular Dynamics Simulations
Fu, T., Zheng, G., Tu, G., Yang, F., Chen, Y., Yao, X., Li, X., Xue, W., & Zhu, F. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00059 · Cited by 115
mTOR, a Potential Target to Treat Autism Spectrum Disorder
Sato, A. (2016) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527315666160413120638 · Cited by 117
Reversal of Fragile X Phenotypes by Manipulation of AβPP/Aβ Levels in Fmr1KO Mice
Westmark, C. J., Westmark, P. R., O'Riordan, K. J., Ray, B. C., Hervey, C. M., Salamat, M. S., Abozeid, S. H., Stein, K. M., Stodola, L. A., Tranfaglia, M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026549 · Cited by 110
Self-citation
CYFIP family proteins between autism and intellectual disability: links with Fragile X syndrome
Abekhoukh, S., & Bardoni, B. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00081 · Cited by 110
Early-onset network hyperexcitability in presymptomatic Alzheimer’s disease transgenic mice is suppressed by passive immunization with anti-human APP/Aβ antibody and by mGluR5 blockade
Kazim, S. F., Chuang, S.-C., Zhao, W., Wong, R. K. S., Bianchi, R., & Iqbal, K. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00071 · Cited by 109
Genetic manipulation of STEP reverses behavioral abnormalities in a fragile X syndrome mouse model
Goebel‐Goody, S. M., Wilson‐Wallis, E. D., Royston, S., Tagliatela, S. M., Naegele, J. R., & Lombroso, P. J. (2012) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2012.00781.x · Cited by 108
Fragile X-associated disorders: a clinical overview
Gallagher, A. T., & Hallahan, B. P. (2011) · Journal of Neurology · doi:10.1007/s00415-011-6161-3 · Cited by 116
Therapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back
Gross, C., Hoffmann, A., Bassell, G. J., & Berry-Kravis, E. M. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0355-9 · Cited by 105
Therapeutic Strategies in Fragile X Syndrome: Dysregulated mGluR Signaling and Beyond
Groß, C., Berry‐Kravis, E., & Bassell, G. J. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.137 · Cited by 109
Autism Spectrum Disorder: Focus on Glutamatergic Neurotransmission
Montanari, M., Martella, G., Bonsi, P., & Meringolo, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073861 · Cited by 114
Pharmacological reversal of synaptic plasticity deficits in the mouse model of Fragile X syndrome by group II mGluR antagonist or lithium treatment
Choi, C. H., Schoenfeld, B. P., Bell, A. J., Hinchey, P., Kollaros, M., Gertner, M. J., Woo, N. H., Tranfaglia, M. R., Bear, M. F., Zukin, R. S., et al. (2010) · Brain Research · doi:10.1016/j.brainres.2010.11.032 · Cited by 107
Self-citation
Fragile X Syndrome and Targeted Treatment Trials
Hagerman, R. J., Lauterborn, J. C., Au, J., & Berry‐Kravis, E. (2011) · Results and problems in cell differentiation · doi:10.1007/978-3-642-21649-7_17 · Cited by 111
Cell-Type-Specific Translation Profiling Reveals a Novel Strategy for Treating Fragile X Syndrome
Thomson, S. R., Seo, S. S., Barnes, S. A., Louros, S. R., Muscas, M., Dando, O., Kirby, C., Wyllie, D. J. A., Hardingham, G. E., Kind, P. C., et al. (2017) · Neuron · doi:10.1016/j.neuron.2017.07.013 · Cited by 100
Channelopathies in fragile X syndrome
Deng, P., & Klyachko, V. A. (2021) · Nature reviews. Neuroscience · doi:10.1038/s41583-021-00445-9 · Cited by 112
Targeted treatments for fragile X syndrome
Berry‐Kravis, E., Knox, A. T., & Hervey, C. (2011) · Journal of Neurodevelopmental Disorders · doi:10.1007/s11689-011-9074-7 · Cited by 108
Fragile X syndrome: From protein function to therapy
Bagni, C., & Oostra, B. A. (2013) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36241 · Cited by 110
Generation and Characterization of Fmr1 Knockout Zebrafish
den Broeder, M. J., van der Linde, H., Brouwer, J. R., Oostra, B. A., Willemsen, R., & Ketting, R. F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007910 · Cited by 102
Glutamate receptor dysfunction and drug targets across models of autism spectrum disorders
Carlson, G. C. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.02.003 · Cited by 102
Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study
Bailey, D. B., Berry‐Kravis, E., Wheeler, A., Raspa, M., Merrien, F., Ricart, J., Koumaras, B., Rosenkranz, G., Tomlinson, M., von Raison, F., et al. (2015) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-015-9134-5 · Cited by 103
Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome
Erickson, C. A., Wink, L. K., Ray, B., Early, M. C., Stiegelmeyer, E., Mathieu-Frasier, L., Patrick, V. B., Lahiri, D. K., & McDougle, C. J. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3022-z · Cited by 105
The Fragile X Family of Disorders: A Model for Autism and Targeted Treatments
Hagerman, R. J., Rivera, S. M., & Hagerman, P. J. (2008) · Current Pediatric Reviews · doi:10.2174/157339608783565770 · Cited by 101
Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice
Gantois, I., Pop, A. S., de Esch, C. E. F., Buijsen, R. A. M., Pooters, T., Gomez-Mancilla, B., Gasparini, F., Oostra, B. A., D’Hooge, R., & Willemsen, R. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.10.059 · Cited by 100
Rescue of fragile X syndrome phenotypes in Fmr1KO mice by a BKCa channel opener molecule
Hébert, B., Pietropaolo, S., Même, S., Laudier, B., Laugeray, A., Doisne, N., Quartier, A., Lefeuvre, S., Got, L., Cahard, D., et al. (2014) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-014-0124-6 · Cited by 100
Group I metabotropic glutamate receptor antagonists alter select behaviors in a mouse model for fragile X syndrome
Thomas, A. M., Bui, N., Perkins, J. R., Yuva‐Paylor, L. A., & Paylor, R. E. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2375-4 · Cited by 104
The fragile X syndrome: exploring its molecular basis and seeking a treatment
Bardoni, B., Davidovic, L., Bensaid, M., & Khandjian, É. W. (2006) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399406010751 · Cited by 106
Synaptic ionotropic glutamate receptors and plasticity are developmentally altered in the CA1 field of Fmr1 knockout mice
Pilpel, Y., Kolleker, A., Berberich, S., Ginger, M., Frick, A., Mientjes, E., Oostra, B. A., & Seeburg, P. H. (2009) · The Journal of Physiology · doi:10.1113/jphysiol.2008.160929 · Cited by 102
Aberrant early-phase ERK inactivation impedes neuronal function in fragile X syndrome
Kim, S. H., Markham, J. A., Weiler, I. J., & Greenough, W. T. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800257105 · Cited by 97
Dysregulation of group-I metabotropic glutamate (mGlu) receptor mediated signalling in disorders associated with Intellectual Disability and Autism
D’Antoni, S., Spatuzza, M., Bonaccorso, C. M., Musumeci, S. A., Ciranna, L., Nicoletti, F., Huber, K. M., & Catania, M. V. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.02.003 · Cited by 97
Fragile X syndrome: a preclinical review on metabotropic glutamate receptor 5 (mGluR5) antagonists and drug development
Pop, A. S., Gomez‐Mancilla, B., Neri, G., Willemsen, R., & Gasparini, F. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3330-3 · Cited by 101
Long-lasting effects of minocycline on behavior in young but not adult Fragile X mice.
Dansie, L. E., Phommahaxay, K., Okusanya, A. G., Uwadia, J., Huang, M., Rotschafer, S. E., Razak, K. A., Ethell, D. W., & Ethell, I. M. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.058 · Cited by 95
Therapeutic Potential of Metabotropic Glutamate Receptor Modulators
Hovelsø, N., Sotty, F., Montezinho, L. P., Pinheiro, P. S., Herrik, K. F., & Mørk, A. (2012) · Current Neuropharmacology · doi:10.2174/157015912799362805 · Cited by 100
Fragile X: translation in action
Bear, M. F., Dölen, G., Osterweil, E., & Nagarajan, N. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301610 · Cited by 94
Neural Mechanisms Underlying Repetitive Behaviors in Rodent Models of Autism Spectrum Disorders
Gandhi, T., & Lee, C. C. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.592710 · Cited by 97
Fmr1 knockout mice show reduced anxiety and alterations in neurogenesis that are specific to the ventral dentate gyrus
Eadie, B. D., Zhang, W. N., Boehme, F., Gil‐Mohapel, J., Kainer, L., Simpson, J. M., & Christie, B. R. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.08.001 · Cited by 95
Origins of Epilepsy in Fragile X Syndrome
Hagerman, P. J., & Stafstrom, C. E. (2009) · Epiliepsy currents/Epilepsy currents · doi:10.1111/j.1535-7511.2009.01309.x · Cited by 95
The therapeutic potential of insulin-like growth factor-1 in central nervous system disorders
Costales, J. L., & Kolevzon, A. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.01.001 · Cited by 98
Group 1 Metabotropic Glutamate Receptor Function and Its Regulation of Learning and Memory in the Aging Brain
Ménard, C., & Quirion, R. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00182 · Cited by 93
mRNA and protein expression for novel GABAA receptors θ and ρ2 are altered in schizophrenia and mood disorders; relevance to FMRP-mGluR5 signaling pathway
Fatemi, S. H., Folsom, T. D., Rooney, R. J., & THURAS, P. D. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.46 · Cited by 94
Activation of the extracellular signal‐regulated kinase pathway contributes to the behavioral deficit of fragile x‐syndrome
Wang, X., Snape, M., Klann, E., Stone, J. G., Singh, A., Petersen, R. B., Castellani, R. J., Casadesús, G., Smith, M. A., & Zhu, X. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07722.x · Cited by 91
The Psychiatric Presentation of Fragile X: Evolution of the Diagnosis and Treatment of the Psychiatric Comorbidities of Fragile X Syndrome
Tranfaglia, M. R. (2011) · Developmental Neuroscience · doi:10.1159/000329421 · Cited by 97
Self-citation
Cholinergic dysfunction in fragile X syndrome and potential intervention: A preliminary 1H MRS study
Kesler, S. R., Lightbody, A. A., & Reiss, A. L. (2009) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.32697 · Cited by 90
Impaired activity-dependent neural circuit assembly and refinement in autism spectrum disorder genetic models
Doll, C. A., & Broadie, K. S. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00030 · Cited by 86
Potential therapeutic interventions for fragile X syndrome
Levenga, J., de Vrij, F. M. S., Oostra, B. A., & Willemsen, R. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.08.005 · Cited by 90
Attentional dysfunction, impulsivity, and resistance to change in a mouse model of fragile X syndrome.
Moon, J., Beaudin, A. E., Verosky, S. C., Driscoll, L. L., Weiskopf, M., Levitsky, D. A., Crnic, L. S., & Strupp, B. J. (2006) · Behavioral Neuroscience · doi:10.1037/0735-7044.120.6.1367 · Cited by 91
Genetic and epigenetic defects in mental retardation
Kramer, J. M., & van Bokhoven, H. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.08.009 · Cited by 91
Fragile X syndrome—From genes to cognition
Schneider, A., Hagerman, R. J., & Hessl, D. R. (2009) · Developmental Disabilities Research Reviews · doi:10.1002/ddrr.80 · Cited by 90
Learning and behavioral deficits associated with the absence of the fragile X mental retardation protein: what a fly and mouse model can teach usPreprint
Santos, A. R., Kanellopoulos, A. K., & Bagni, C. (2014) · Learning & Memory · doi:10.1101/lm.035956.114 · Cited by 91
FMR1 premutation and full mutation molecular mechanisms related to autism
Hagerman, R., Au, J., & Hagerman, P. (2011) · Journal of Neurodevelopmental Disorders · doi:10.1007/s11689-011-9084-5 · Cited by 85
Enhanced markers of oxidative stress, altered antioxidants and NADPH-oxidase activation in brains from fragile X mental retardation 1-deficient mice, a pathological model for fragile X syndrome
El Bekay, R., Romero‐Zerbo, Y., Decara, J., Sanchez‐Salido, L., Del Arco‐Herrera, I., Rodríguez‐de Fonseca, F., & De Diego‐Otero, Y. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05939.x · Cited by 85
Novel West syndrome candidate genes in a Chinese cohort
Peng, J., Wang, Y., He, F., Chen, C., Wu, L., Yang, L., Ma, Y., Zhang, W., Shi, Z., Chen, C., et al. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12860 · Cited by 86
Over-inhibition: a model for developmental intellectual disability
Fernandez, F., & Garner, C. C. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.07.005 · Cited by 87
Dysregulation of fragile × mental retardation protein and metabotropic glutamate receptor 5 in superior frontal cortex of individuals with autism: a postmortem brain study
Fatemi, S. H., & Folsom, T. D. (2011) · Molecular Autism · doi:10.1186/2040-2392-2-6 · Cited by 84
Mechanism-Based Treatments in Neurodevelopmental Disorders: Fragile X Syndrome
Berry‐Kravis, E. (2013) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2013.12.001 · Cited by 86
Impairments in dendrite morphogenesis as etiology for neurodevelopmental disorders and implications for therapeutic treatments
Copf, T. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.04.008 · Cited by 92
Deletion of Fmr1 from Forebrain Excitatory Neurons Triggers Abnormal Cellular, EEG, and Behavioral Phenotypes in the Auditory Cortex of a Mouse Model of Fragile X Syndrome
Lovelace, J. W., Rais, M., Palacios, A. R., Shuai, X. S., Bishay, S., Popa, O., Pirbhoy, P. S., Binder, D. K., Nelson, D. L., Ethell, I. M., et al. (2019) · Cerebral Cortex · doi:10.1093/cercor/bhz141 · Cited by 82
The Cyclic AMP Cascade Is Altered in the Fragile X Nervous System
Kelley, D. J., Davidson, R. J., Elliott, J. L., Lahvis, G. P., Yin, J. C. P., & Bhattacharyya, A. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000931 · Cited by 87
Hippocampal dysfunction and cognitive impairment in Fragile-X Syndrome
Bostrom, C. A., Yau, S., Majaess, N. M., Vetrici, M. A., Gil‐Mohapel, J., & Christie, B. R. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.06.033 · Cited by 87
The role of fragile X mental retardation protein in major mental disorders
Fatemi, S. H., & Folsom, T. D. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.11.011 · Cited by 80
The Metabotropic Glutamate Receptor Subtype 5 Antagonist Fenobam Is Analgesic and Has Improved in Vivo Selectivity Compared with the Prototypical Antagonist 2-Methyl-6-(phenylethynyl)-pyridine
Montana, M. C., Cavallone, L. F., Stubbert, K., Stefanescu, A. D., Kharasch, E. D., & Gereau, R. W. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.154138 · Cited by 80
NNZ-2566, a novel analog of (1–3) IGF-1, as a potential therapeutic agent for fragile X syndrome
Deacon, R. M. J., Glass, L., Snape, M., Hurley, M. J., Altimiras, F. J., Biekofsky, R. R., & Cogram, P. (2015) · NeuroMolecular Medicine · doi:10.1007/s12017-015-8341-2 · Cited by 78
Brief Report: Sensorimotor Gating in Idiopathic Autism and Autism Associated with Fragile X Syndrome
Yuhas, J. M., Cordeiro, L., Tassone, F., Ballinger, E. C., Schneider, A., Long, J. M., Ornitz, E. M., & Hessl, D. R. (2010) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-010-1040-9 · Cited by 78
Translational Concepts of mGluR5 in Synaptic Diseases of the Brain
Piers, T. M., Kim, D. H., Kim, B. C., Regan, P. L., Whitcomb, D. J., & Cho, K. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00199 · Cited by 80
Early continuous inhibition of group 1 mGlu signaling partially rescues dendritic spine abnormalities in the Fmr1 knockout mouse model for fragile X syndrome
Su, T., Fan, H.-X., Jiang, T., Sun, W.-W., Den, W.-Y., Gao, M.-M., Chen, S.-Q., Zhao, Q.-H., & Yi, Y.-H. (2011) · Psychopharmacology · doi:10.1007/s00213-010-2130-2 · Cited by 76
mGlu5negative allosteric modulators: a patent review (2013 - 2016)
Emmitte, K. A. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1280466 · Cited by 77
Drosophila strategies to study psychiatric disorders
van Alphen, B., & van Swinderen, B. (2011) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.09.007 · Cited by 77
Genetic reduction of group 1 metabotropic glutamate receptors alters select behaviors in a mouse model for fragile X syndrome
Thomas, A. M., Bui, N., Graham, D. F., Perkins, J. R., Yuva‐Paylor, L. A., & Paylor, R. E. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.04.049 · Cited by 74
Impaired Critical Period Plasticity in Primary Auditory Cortex of Fragile X Model Mice
Kim, H., Gibboni, R., Kirkhart, C., & Bao, S. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.3246-12.2013 · Cited by 74
Regulation of molecular pathways in the Fragile X Syndrome: insights into Autism Spectrum Disorders
De Rubeis, S., & Bagni, C. (2011) · Journal of Neurodevelopmental Disorders · doi:10.1007/s11689-011-9087-2 · Cited by 73
Discovery of Molecular Switches That Modulate Modes of Metabotropic Glutamate Receptor Subtype 5 (mGlu5) Pharmacology in Vitro and in Vivo within a Series of Functionalized, Regioisomeric 2- and 5-(Phenylethynyl)pyrimidines
Sharma, S., Kedrowski, J., Rook, J. M., Smith, R. L., Jones, C. K., Rodriguez, A. L., Conn, P. J., & Lindsley, C. W. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900654c · Cited by 73
The PI3K signaling pathway as a pharmacological target in Autism related disorders and Schizophrenia
Enríquez-Barreto, L., & Morales, M. (2016) · Journal of Green Engineering · doi:10.1186/s40591-016-0047-9 · Cited by 73
Recent advances in gene therapy for neurodevelopmental disorders with epilepsy
Turner, T. J., Zourray, C., Schorge, S., & Lignani, G. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15168 · Cited by 71
Treatment with valproic acid ameliorates ADHD symptoms in fragile X syndrome boys
Torrioli, M., Vernacotola, S., Setini, C., Bevilacqua, F., Martinelli, D., Snape, M., Hutchison, J. A., Di Raimo, F. R., Tabolacci, E., & Neri, G. (2010) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.33484 · Cited by 71
Selective Role of the Catalytic PI3K Subunit p110β in Impaired Higher Order Cognition in Fragile X Syndrome
Gross, C., Raj, N., Molinaro, G., Allen, A. G., Whyte, A. J., Gibson, J. R., Huber, K. M., Gourley, S. L., & Bassell, G. J. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.065 · Cited by 71
Intracellular calcium dysregulation in autism spectrum disorder: An analysis of converging organelle signaling pathways
Nguyen, R. L., Medvedeva, Y. V., Ayyagari, T., Schmunk, G., & Gargus, J. J. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2018.08.003 · Cited by 71
Audiogenic seizure susceptibility is reduced in fragile X knockout mice after introduction of FMR1 transgenes
Musumeci, S. A., Calabrese, G., Bonaccorso, C. M., D'Antoni, S., Brouwer, J. R., Bakker, C. E., Elia, M., Ferri, R., Nelson, D. L., Oostra, B. A., et al. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2006.08.007 · Cited by 70
Recent Advances in the Design and Development of Novel Negative Allosteric Modulators of mGlu5
Emmitte, K. A. (2011) · ACS Chemical Neuroscience · doi:10.1021/cn2000266 · Cited by 70
Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives
Persico, A. M., Arango, C., Buitelaar, J. K., Correll, C. U., Glennon, J. C., Hoekstra, P. J., Moreno, C., Vitiello, B., Vorstman, J. A. S., & Zuddas, A. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.06.009 · Cited by 73
Multiple behavior phenotypes of the fragile-X syndrome mouse model respond to chronic inhibition of phosphodiesterase-4D (PDE4D)
Gurney, M. E., Cogram, P., Deacon, R. M., Rex, C., & Tranfaglia, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-15028-x · Cited by 69
Self-citation
The contribution of inhibitory interneurons to circuit dysfunction in Fragile X Syndrome
Rio, C. A. C.-D., & Huntsman, M. M. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00245 · Cited by 69
Reliability of Eye Tracking and Pupillometry Measures in Individuals with Fragile X Syndrome
Farzin, F., Huang, F. S., Hervey, C., Berry‐Kravis, E., & Hessl, D. R. (2011) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-011-1176-2 · Cited by 72
Unstable Mutations in the FMR1 Gene and the Phenotypes
Loesch, D. Z., & Hagerman, R. J. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5434-2_6 · Cited by 67
Which Comes First in Fragile X Syndrome, Dendritic Spine Dysgenesis or Defects in Circuit Plasticity?
Portera‐Cailliau, C. (2011) · The Neuroscientist · doi:10.1177/1073858410395322 · Cited by 72
Glycogen Synthase Kinase-3: A Promising Therapeutic Target for Fragile X Syndrome
Mines, M. A., & Jope, R. S. (2011) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2011.00035 · Cited by 68
Brief Report: Acamprosate in Fragile X Syndrome
Erickson, C. A., Mullett, J. E., & McDougle, C. J. (2010) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-010-0988-9 · Cited by 67
Audiogenic Seizures in theFmr1Knock-Out Mouse Are Induced byFmr1Deletion in Subcortical, VGlut2-Expressing Excitatory Neurons and Require Deletion in the Inferior Colliculus
Gonzalez, D., Tomasek, M. P., Hays, S. A., Sridhar, V., Ammanuel, S. G., Chang, C.-W., Pawlowski, K. S., Huber, K. M., & Gibson, J. R. (2019) · Journal of Neuroscience · doi:10.1523/jneurosci.0886-19.2019 · Cited by 64
Cellular Plasticity for Group I mGluR-Mediated Epileptogenesis
Bianchi, R., Chuang, S.-C., Zhao, W., Young, S. R., & Wong, R. K. S. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.5447-08.2009 · Cited by 67
Neurodevelopmental effects of chronic exposure to elevated levels of pro-inflammatory cytokines in a developing visual system
Lee, R., Mills, E. A., Schwartz, N., Bell, M. R., Deeg, K. E., Ruthazer, E. S., Marsh‐Armstrong, N., & Aizenman, C. D. (2010) · Neural Development · doi:10.1186/1749-8104-5-2 · Cited by 66
FMRP Expression Levels in Mouse Central Nervous System Neurons Determine Behavioral Phenotype
Arsenault, J., Gholizadeh, S., Niibori, Y., Pacey, L. K. K., Halder, S. K., Koxhioni, E., Konno, A., Hirai, H., & Hampson, D. R. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.090 · Cited by 69
Mechanistic relationships between Drosophila fragile X mental retardation protein and metabotropic glutamate receptor A signaling
Pan, L., Woodruff, E. A., Liang, P., & Broadie, K. S. (2008) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2008.01.003 · Cited by 68
Complex effects of mGluR5 antagonism on sociability and stereotypic behaviors in mice: Possible implications for the pharmacotherapy of autism spectrum disorders
Burket, J. A., Herndon, A. L., Winebarger, E. E., Jacome, L. F., & Deutsch, S. I. (2011) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.08.001 · Cited by 65
Neuroanatomical, molecular genetic, and behavioral correlates of fragile X syndrome
Koukoui, S., & Chaudhuri, A. (2006) · Brain Research Reviews · doi:10.1016/j.brainresrev.2006.06.001 · Cited by 65
Fragile X mental retardation protein: A paradigm for translational control by RNA-binding proteins
Chen, E., & Joseph, S. (2015) · Biochimie · doi:10.1016/j.biochi.2015.02.005 · Cited by 66
β-Arrestin2 Couples Metabotropic Glutamate Receptor 5 to Neuronal Protein Synthesis and Is a Potential Target to Treat Fragile X
Stoppel, L. J., Auerbach, B. D., Senter, R. K., Preza, A. R., Lefkowitz, R. J., & Bear, M. F. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.075 · Cited by 67
What’s hAPPening at synapses? The role of amyloid β-protein precursor and β-amyloid in neurological disorders
Westmark, C. J. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.122 · Cited by 63

Authors: Yan, Q. J., Rammal, M., Tranfaglia, M., & Bauchwitz, R. P.
Affiliations: Columbia University (US)
Fraxa Research Foundation (US)
Corresponding author: Bauchwitz, R.P.
ORCID: Bauchwitz, R.P.
Venue: Neuropharmacology
Publisher: Elsevier BV
Published: 2005-12
Volume: 49
Issue: 7
Pages: 1053-1066
ISSN: 0028-3908 (ISSN-L)
DOI: 10.1016/j.neuropharm.2005.06.004
OpenAlex: W2094993063
Cited by: 521
References: 60
Citations by year: 2026: 6 · 2025: 7 · 2024: 8 · 2023: 10 · 2022: 12 · 2021: 16 · 2020: 13 · 2019: 10 · 2018: 12 · 2017: 28 · 2016: 26 · 2015: 26 · 2014: 30 · 2013: 45 · 2012: 47
FWCI: 13.31
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
doi.org/10.15223/policy-017 (stm-asf)
doi.org/10.15223/policy-037 (stm-asf)
doi.org/10.15223/policy-012 (stm-asf)
doi.org/10.15223/policy-029 (stm-asf)
doi.org/10.15223/policy-004 (stm-asf)
Locations: Neuropharmacology (publishedVersion)
PubMed (publishedVersion)
CogPrints (University of Southampton) (submittedVersion)
Funders: FRAXA Research Foundation
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
Keywords: fragile X syndrome, FMR1 gene, mGluR5, MPEP, audiogenic seizures, testicular enlargement, FMRP, drug tolerance, seizure susceptibility, mouse model
MeSH terms: Aging, Alleles, Animals, Drug Synergism, Exploratory Behavior, Female, Fragile X Syndrome, Genotype, Male, Mice, Inbred C57BL, Phenotype, Pyridines, Receptors, Metabotropic Glutamate, Epilepsy, Reflex, Mice, Fragile X Messenger Ribonucleoprotein 1, Receptor, Metabotropic Glutamate 5

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks